Theranostic radiopharmaceutical compositions and methods for targeted infectious disease diagnosis and treatment are provided. The theranostic radiopharmaceutical compositions may include a conjugate of a nucleoside analog, a chelator, and a radionuclide label.

Compositions and methods for the diagnosis and treatment of infectious diseases, including for the diagnosis and treatment of Cytokine Storm and Cytokine Release Syndrome. The compositions may include a conjugate of a nucleoside analog, a chelator, and a label for use as imaging and therapeutic agents.

Compositions and methods for the personalized and targeted therapeutic treatment of diseases and disorders, including the treatment of pain, inflammation, and infectious diseases in a subject. In particular, labeled natural cannabinoid therapeutic compositions are provided that include a conjugate of a natural cannabinoid compound, a chelator, and a label, that when coupled with imaging may be used to determine in real time optimal dosing and targeting of particular pathways and tissues to provide personalized therapies. Combination therapies are also provided that include one or more natural cannabinoid compound and at least one active pharmaceutical ingredient.

A nanoparticle is provided. The nanoparticle includes a magnetic core including a magnetic nanocrystal, a fluorophore coupled to the magnetic core, at least one chelating compound coupled to the magnetic core, the at least one chelating compound being a compound that chelates copper-64 (.sup.64Cu), a compound that chelates technetium-99m (.sup.99mTc), or a combination thereof, and an iodine chelator coupled to the magnetic core. Methods of making the nanoparticle and of using the nanoparticle as a multi-modal contrast agent are also provided.

The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.

Neurokinin-1 (NK-1) receptor-binding agent delivery conjugates, compositions comprising NK-1 receptor-binding agent delivery conjugates, and methods for making and administering NK-1 receptor-binding agent delivery conjugates are provided. A conjugate may include an NK-1 receptor-binding moiety, a linker group containing at least one linker selected from the group of a releasable linker and a spacer linker, and an active agent linked to the linker group. The active agent may be selected from the group of fluorophore-containing compounds, radionuclide-containing compounds, and therapeutic agents for treatment of tumor cells characterized by over-expression of the NK-1 receptor.

Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

This invention relates to a chemistry branch, particularly to the field of compounds' organic synthesis that belongs to the aromatic bicyclic or naphthalene category, used in the detection of amyloid sheets. These new naphthalene derivatives have a general formula: Wherein R represents mutually independent groups. In I: R.sub.1:-alkylenyl-C(O)NH-alkylenyl-R.sub.3, -alkylenyl-C(O)O—R.sub.4, R.sub.3:—COOH, —OH, —SH, —NH.sub.2, -alkyl-NH-alkyl-N-dithiocarbamate alkaline earth metal salts, R.sub.4: H, succinimidyl group, R.sub.2: —H,-alkyl. In II: R.sub.1: -alkyl, -alkylenyl-halide-alkylenyl-hydroxyl-alkylenyl-O-aryl, —O-alkylsulfonate alkylenyl, R.sub.2: -halide-alkylenyl-O-aryl, -alkylenyl-O-alkylsulfonate, -alkylenyl-halide-, —CH(O), —HC═C(CN).sub.2, —HC═CHNO.sub.2, -alkylenyl-NH.sub.2, -alkylenyl-NH-alkyl, -alkylenyl-alkyl-N-dithiocarbamate alkaline salts. The terms “alkyl” and “alkylenyl” refer to linear or branched aliphatic chains, preferably from 1 to 4 carbon atoms and the term halide to fluorine, bromine or iodine. These compounds are neutral, lipophilic and have low molecular weight and therefore they cross the blood brain barrier and attach to the amyloid sheets. The present invention provides procedures for obtaining naphthalene derivatives with good yields, which can be practical, economical and adapted to a larger-scale manufacturing. We are unaware whether the compounds presented in this invention have been previously reported.

A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor. ##STR00001##

Described herein are Tz/TCO-based pretargeting strategies using an Al[.sup.18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based .sup.18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, .sup.18F is more readily available to produce and therefore integrated into hospital workflows.